Xeroderma pigmentosum group A with mutational hot spot (c.390-1G>C in XPA) in South Korea.
- Author:
Jung Yoon CHOI
1
;
Hyung Ho YUN
;
Cha Gon LEE
Author Information
- Publication Type:Original Article
- Keywords: Xeroderma pigmentosum; complementation group A; XPA gene; Hereditary neurodegenerative disease; High throughput nucleotide sequencing
- MeSH: Child, Preschool; Diagnosis; Diagnosis, Differential; DNA Repair; Exome; Female; Genetic Heterogeneity; Genome; Heredodegenerative Disorders, Nervous System; High-Throughput Nucleotide Sequencing; Humans; Ichthyosis*; Insurance, Health; Japan; Korea*; Prevalence; Ultraviolet Rays; Xeroderma Pigmentosum*
- From:Journal of Genetic Medicine 2016;13(1):20-25
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: Xeroderma pigmentosum (XP) is rare autosomal recessive genetic disorder of DNA repair in which the ability to repair damage caused by ultraviolet light is deficient. We reported the first molecularly confirmed Korean patient of XP by targeted exome sequencing. The prevalence of XP included all subtype and carrier frequency of XP-A the using public data were estimated for the first time in South Korea. MATERIALS AND METHODS: We described a 4-year-old Korean girl with clinical diagnosis of XP. We performed targeted exome sequencing in the patient for genetic confirmation considering disease genetic heterogeneity and for differential diagnosis. We verified a carrier frequency of c.390-1G>C in XPA gene known as mutational hot spot using Korean Reference Genome Data Base. We estimated the period prevalence of all subtypes of XP based on claims data of the Health Insurance Review and Assessment Service in South Korea. RESULTS: We identified homozygous splicing mutation of XPA (c.390-1G>C) in the patient. The carrier frequency of risk for XPA (c.390-1G>C) was relatively high 1.608 e-03 (allele count 2/1244). The prevalence of XP in South Korea was 0.3 per million people. CONCLUSION: We expect that c.390-1G>C is hot spot for the mutation of XPA and possible founder variant in South Korea. However, the prevalence in South Korea was extremely low compared with Western countries and Japan.
